Short answer
USANA HEALTH SCIENCES INC (USNA) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 27, 2025. Quarterly revenue was $214M (up 6.7% year over year) with net income of −$7M.
Q3 2025 key financials · XBRL
- Revenue
- $214M
- +6.7% YoY · −9.4% QoQ
- Net income
- −$7M
- −161.5% YoY · −167.6% QoQ
- Operating margin
- 0.6%
- Gross margin
- 77.2%
- EPS (diluted)
- −$0.34
- −160.7% YoY · −165.4% QoQ
Source: XBRL data from the USANA HEALTH SCIENCES INC (USNA) Q3 2025 10-Q on SEC EDGAR. USD.
USANA HEALTH SCIENCES INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $213.7M, up 6.7% YoY from $200.2M, driven by Hiya sales of $30.8M
- Gross margin 77.2% vs 80.4% YoY; operating margin 0.6% vs 7.8%
- Best performer: Hiya revenue $30.8M; worst: direct selling revenue $182.8M, down 8.7%
- Net loss $6.5M vs $10.6M net income; effective tax rate 65% vs 45% quarterly estimate
- Outlook: softer Brand Partner productivity during compensation-plan rollout; fourth-quarter training and education focus
Risk Factors
- No material changes to 2024 Form 10-K risk factors
- Share-repurchase authorization $34.0 million at September 27, 2025
- No common-stock purchases during quarter ended September 27, 2025
- No director or officer Rule 10b5-1 arrangements adopted, modified, or terminated
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other USANA HEALTH SCIENCES INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.